Published in Biochem Pharmacol on October 01, 1969
Modulators of nucleoside metabolism in the therapy of brain diseases. Curr Top Med Chem (2011) 0.83
Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer. J Med Chem (1995) 3.72
Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer (2004) 3.32
Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase). J Steroid Biochem Mol Biol (1994) 3.19
The synthesis of oligoribonucleotides. IV. Preparation of dinucleoside phosphates from 2',5'-protected ribonucleoside derivatives. Tetrahedron (1968) 2.31
Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P450(17alpha) inhibitors. J Steroid Biochem Mol Biol (1997) 1.94
Isolation and identification of products from alkylation of nucleic acids: ethyl- and isopropyl-purines. Biochem J (1975) 1.62
Reaction products from N-methyl-N-nitrosourea and deoxyribonucleic acid containing thymidine residues. Synthesis and identification of a new methylation product, O4-methylthymidine. Biochem J (1973) 1.50
Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoral drug concentration. Lancet (1994) 1.49
The alkylation of 2'-deoxyguanosine and of thymidine with diazoalkanes. Some observations on o-alkylation. Biochem J (1973) 1.43
The synthesis of oligoribonucleotides. II. Methoxymethylidene derivatives of ribonucleosides and 5'-ribonucleotides. Tetrahedron (1967) 1.39
Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma. Lancet (1980) 1.38
Chemical trapping of a reactive metabolite. The metabolism of the AZO-mustard 2'-carboxy-4-di-(2-chloroethyl)amino-2-methylazobenzene. Biochem Pharmacol (1972) 1.38
Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and isophosphamide. Biochem Pharmacol (1974) 1.29
Alkylation by propylene oxide of deoxyribonucleic acid, adenine, guanosine and deoxyguanylic acid. Biochem J (1972) 1.23
Esters of 3-pyridylacetic acid that combine potent inhibition of 17 alpha-hydroxylase/C17,20-lyase (cytochrome P45017 alpha) with resistance to esterase hydrolysis. J Med Chem (1995) 1.15
The structure of telomycin. J Am Chem Soc (1968) 1.14
High dose melphalan and non-cryopreserved autologous bone marrow treatment of malignant melanoma and neuroblastoma. Exp Hematol (1979) 1.13
Phase I and pharmacokinetic study of D-limonene in patients with advanced cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee. Cancer Chemother Pharmacol (1998) 1.10
Neonatal circumcision. Urol Clin North Am (1995) 1.08
3- and 4-pyridylalkyl adamantanecarboxylates: inhibitors of human cytochrome P450(17 alpha) (17 alpha-hydroxylase/C17,20-lyase). Potential nonsteroidal agents for the treatment of prostatic cancer. J Med Chem (1996) 1.07
Analogues of aminoglutethimide: selective inhibition of cholesterol side-chain cleavage. J Med Chem (1983) 1.00
A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in Walker carcinoma cells. Biochem Pharmacol (1988) 0.97
Inhibition of protein prenylation by metabolites of limonene. Biochem Pharmacol (1999) 0.97
Pharmacokinetics of the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB3717) in the mouse. Cancer Treat Rep (1986) 0.97
The synthesis of a DOPA analogue, 1-amino-2-(3, 4-dihydroxyphenyl)-ethylphosphonic acid and distribution studies in mice bearing the Harding-Passey melanoma. Chem Biol Interact (1974) 0.96
Inhibitory effect of simvastatin on the proliferation of human myeloid leukaemia cells in severe combined immunodeficient (SCID) mice. Br J Haematol (1998) 0.94
Identification of novel reduced pyridinium derivatives as synthetic co-factors for the enzyme DT diaphorase (NAD(P)H dehydrogenase (quinone), EC 1.6.99.2). Biochem Pharmacol (1992) 0.94
Effect of oestrogen receptor status and time on the intra-tumoural accumulation of tamoxifen and N-desmethyltamoxifen following short-term therapy in human primary breast cancer. Breast Cancer Res Treat (1993) 0.93
The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth. Cancer Chemother Pharmacol (1994) 0.92
Pantaloon spica cast: an effective method for postoperative immobilization after free graft hypospadias repair. J Urol (1997) 0.91
Inhibition of 17 alpha-hydroxylase/C17-C20 lyase by bifluranol and its analogues. J Steroid Biochem (1989) 0.90
Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2. J Med Chem (1990) 0.90
The quantitation of cyclophosphamide in human blood and urine by mass spectrometry-stable isotope dilution. Clin Chim Acta (1975) 0.90
Septic arthritis secondary to vesicoureteral reflux into single ectopic ureter. Pediatr Nephrol (1999) 0.89
Pharmaco-kinetics of melphalan following oral or intravenous administration in patients with malignant disease. Eur J Cancer (1978) 0.89
Metabolism of aminoglutethimide in humans: identification of hydroxylaminoglutethimide as an induced metabolite. Biomed Mass Spectrom (1983) 0.89
Reduced genotoxicity of [D5-ethyl]-tamoxifen implicates alpha-hydroxylation of the ethyl group as a major pathway of tamoxifen activation to a liver carcinogen. Carcinogenesis (1994) 0.88
Analogues of aminoglutethimide: selective inhibition of aromatase. J Med Chem (1985) 0.87
Pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen, new analogues of the antiestrogen tamoxifen for the treatment of breast cancer. Cancer Res (1991) 0.87
Comparative metabolism of 2-[bis(2-chloroethyl)amino]tetrahydro-2-H-1,3,2-oxazaphosphorine-2-oxide (cyclophosphamide) and its enantiomers in humans. Cancer Res (1979) 0.87
Management of prepubertal varicoceles-results of a questionnaire study among pediatric urologists and urologists with infertility training. Urology (2001) 0.86
Polymorphically acetylated aminoglutethimide in humans. Br J Cancer (1982) 0.86
The appendix as right ureteral substitute in children. J Urol (2000) 0.85
Derivatives of tamoxifen. Dependence of antiestrogenicity on the 4-substituent. J Med Chem (1989) 0.85
Gastrocystoplasty: long-term complications in 22 patients. J Urol (1999) 0.85
Lysosomal changes and enhanced metastatic growth: an experimental study of the effects of some non-ionic surfactants. Int J Cancer (1971) 0.85
Analysis of phase I and phase II metabolites of tamoxifen in breast cancer patients. Drug Metab Dispos (1994) 0.85
Salvage continent vesicostomy after enterocystoplasty in the absence of the appendix. J Urol (1999) 0.85
Virtual cofactors for an Escherichia coli nitroreductase enzyme: relevance to reductively activated prodrugs in antibody directed enzyme prodrug therapy (ADEPT). Biochem Pharmacol (1995) 0.84
Comparison between inhibition of protein kinase C and antagonism of calmodulin by tamoxifen analogues. Biochem Pharmacol (1995) 0.84
Effects of a new antioestrogen, idoxifene, on cisplatin- and doxorubicin-sensitive and -resistant human ovarian carcinoma cell lines. Br J Cancer (1994) 0.84
Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione in patients with postmenopausal breast cancer. Cancer Chemother Pharmacol (1991) 0.84
Structure and reactivity of nitrosocimetidine. Cancer Lett (1980) 0.83
Tamoxifen induces selective membrane association of protein kinase C epsilon in MCF-7 human breast cancer cells. Int J Cancer (1998) 0.83
Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis. Cancer Res (1999) 0.82
Ureteral triplication with ectopic upper pole moiety. Urology (2001) 0.82
Chemotherapy of cancer. Chem Br (1970) 0.82
Metabolism of tamoxifen by rat liver microsomes: formation of the N-oxide, a new metabolite. Biochem Pharmacol (1980) 0.82
Idoxifene: report of a phase I study in patients with metastatic breast cancer. Cancer Res (1995) 0.82
Isotope effects in O- and N-demethylations mediated by rat liver microsomes: an application of direct insertion electron impact mass spectrometry. Chem Biol Interact (1974) 0.82
The effect of macromolecules upon the rates of hydrolysis of aromatic nitrogen mustard derivatives. Chem Biol Interact (1971) 0.82
The metabolism of deuterated analogues of chlorambucil by the rat. Chem Biol Interact (1979) 0.82
Identification and characterization of limonene metabolites in patients with advanced cancer by liquid chromatography/mass spectrometry. Drug Metab Dispos (1996) 0.82
Enzyme inhibition by phosphonate analogues of dTTP. Adv Exp Med Biol (1984) 0.81
Identification, synthesis and properties of 5-(aziridin-1-yl)-2-nitro-4-nitrosobenzamide, a novel DNA crosslinking agent derived from CB1954. Biochem Pharmacol (1993) 0.81
Analogues of 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione as selective inhibitors of aromatase: derivatives with variable 1-alkyl and 3-alkyl substituents. J Med Chem (1987) 0.80
An economic synthesis of 1,2,3,4-tetra-O-acetyl-5-thio-D-xylopyranose and its transformation into 4-substituted-phenyl 1,5-dithio-D- xylopyranosides possessing antithrombotic activity. Carbohydr Res (1998) 0.80
Vaginal construction in children. J Urol (1998) 0.80
Renal ultrasound changes after internal double-J stented pyeloplasty for ureteropelvic junction obstruction. Tech Urol (2001) 0.80
Metabolism of tamoxifen by isolated rat hepatocytes. Identification of the glucuronide of 4-hydroxytamoxifen. Biochem Pharmacol (1990) 0.80
Metabolism of aniline mustard (N,N-di-(2-chloroethyl)aniline). Biochem Pharmacol (1973) 0.80
Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione ('pyridoglutethimide') in postmenopausal breast cancer patients. Br J Cancer (1991) 0.80
Marrow autotransplantation accelerates haematological recovery in patients with malignant melanoma treated with high-dose melphalan. Br J Cancer (1979) 0.80
Hydroxy derivatives of tamoxifen. J Med Chem (1985) 0.79
Insurability of children with congenital urological anomalies. J Urol (1997) 0.79
Homologs of idoxifene: variation of estrogen receptor binding and calmodulin antagonism with chain length. J Med Chem (1996) 0.79
Evidence that tamoxifen binds to calmodulin in a conformation different to that when binding to estrogen receptors, through structure-activity study on ring-fused analogues. Biochem Pharmacol (1994) 0.79
Synthesis of 1,4-dideoxy-1,4-imino-D-glucitol, a glucosidase inhibitor. Carbohydr Res (1986) 0.78
The metabolism of N-nitrosomorpholine by rat liver microsomes and its oxidation by the Fenton system. Carcinogenesis (1986) 0.78
The metabolism of the anti-tumour agent 5-(1-aziridinyl)-2,4-dinitrobenzamide (CB 1954). Biochem Pharmacol (1976) 0.78
Variation of the inhibition of calmodulin dependent cyclic AMP phosphodiesterase amongst analogues of tamoxifen; correlations with cytotoxicity. Biochem Pharmacol (1990) 0.78
New endocrine agents for the treatment of breast cancer. Recent Results Cancer Res (1993) 0.78
Medicolegal aspects of testicular torsion. Urology (2001) 0.78
Toxicity, antitumour and haematological effects of 1,2-anhydro-6-bromogalactitol and d-mannitol: a comparison with the related dibromo- and dianhydro-derivatives. Eur J Cancer Clin Oncol (1982) 0.78
Non-isomerisable antiestrogens related to tamoxifen. J Steroid Biochem (1988) 0.78
A mechanistic hypothesis for DNA adduct formation by tamoxifen following hepatic oxidative metabolism. Carcinogenesis (1994) 0.78
Metabolism of tamoxifen by isolated rat hepatocytes: anti-estrogenic activity of tamoxifen N-oxide. Biochem Pharmacol (1982) 0.77
Reversal of P-glycoprotein-mediated multidrug resistance by pure anti-oestrogens and novel tamoxifen derivatives. Biochem Pharmacol (1994) 0.77
Effects of 4-hydroxyandrost-4-ene-3,17-dione and its metabolites on 5 alpha-reductase activity and the androgen receptor. J Enzyme Inhib (1992) 0.77
A cancer research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen. Cancer Chemother Pharmacol (2004) 0.77
The novel anti-oestrogen idoxifene inhibits the growth of human MCF-7 breast cancer xenografts and reduces the frequency of acquired anti-oestrogen resistance. Br J Cancer (1997) 0.76
Idoxifene is equipotent to tamoxifen in inhibiting mammary carcinogenesis but forms lower levels of hepatic DNA adducts. Br J Cancer (1997) 0.76
Rationally designed analogues of tamoxifen with improved calmodulin antagonism. J Med Chem (1995) 0.76
The rectus myofascial wrap in the management of urethral sphincter incompetence. BJU Int (2002) 0.76
Length increase of the side chain of idoxifene does not improve its antagonistic potency in breast-cancer cell lines. Cancer Chemother Pharmacol (1998) 0.76
The Mainz II pouch: experience in 5 patients with bladder exstrophy. J Urol (1999) 0.75
Formation of 4-ketocyclophosphamide by the oxidation of cyclophosphamide with KMnO4. Experientia (1973) 0.75
Audiotaping the heart surgery consultation: qualitative study of patients' experiences. Heart (2005) 0.75
Epidemiology, diagnosis, precautions, and policies of intraoperative anaphylaxis to latex. J Am Coll Surg (1996) 0.75